metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology Should donation after cardiac death liver grafts be used for retransplantation?
Información de la revista
Vol. 10. Núm. 4.
Páginas 482-485 (octubre - diciembre 2011)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Visitas
1003
Vol. 10. Núm. 4.
Páginas 482-485 (octubre - diciembre 2011)
Open Access
Should donation after cardiac death liver grafts be used for retransplantation?
Visitas
1003
Dana K. Perry*, Darrin L. Willingham*, Lena Sibulesky*, Ilynn G. Bulatao*, Justin H. Nguyen*, C. Burcin Taner
,
Autor para correspondencia
taner.burcin@mayo.edu

Correspondence and reprint request:
* Department of Transplantation. Mayo Clinic Florida, Jacksonville, Florida, USA.
Este artículo ha recibido

Under a Creative Commons license
Información del artículo
Resumen
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Tablas (3)
Table 1.. Demographic data of the recipients.
Table 2.. Donor and operative data.
Table 3.. Post-operative outcomes.
Mostrar másMostrar menos
Abstract

Introduction. Donation after cardiac death (DCD) donors provide an important source of livers that has been used to expand the donor pool. As a consequence of increased numbers of OLT, allograft failure due to early and late complications and disease recurrence are more commonly encountered. The only life saving treatment for patients with liver allograft failure is liver re-transplantation (LR). The use of DCD liver grafts for LR is controversial.

Material and methods. Between February 1998 and June 2008, 10 patients underwent LR with DCD allografts. Five (50%) patients had no post operative complications. The 30 day, 1 year, and 3 year patient survival are 80, 60, and 60%, respectively. When DCD grafts are used for sick patients with high MELD scores for LR, the patient and graft survivals are prohibitively low.

Conclusion. We do not recommend utilization of DCD liver grafts for LR if a candidate recipient has moderate to high MELD score.

Keywords:
Donation after cardiac death
Liver retransplantation
Texto completo
Introduction

Orthotopic liver transplantation (OLT) is a life saving procedure for patients with end stage disease. There is a significant disparity between organ availability and the number of patients waiting for OLT. Donation after cardiac death (DCD) donors provide an important source of livers that has been used to expand the donor pool. DCD livers are considered inferior grafts because of higher risk for primary non-function (PNF), hepatic artery thrombosis (HAT), and ischemic cholangiopathy (IC). We previously reported our experience in 108 DCD liver recipients.1 Our liver transplant program now has performed over 200 OLT using liver grafts from DCD donors between 1998–2010.

In the last two decades, improved patient survival after OLT has been seen as a result of refined surgical technique, improved peri-operative care of the recipient and advances in immunosuppression.2 As a consequence of increased numbers of OLT, allograft failure due to early and late complications and disease recurrence are more commonly encountered. The only life saving treatment for patients with liver allograft failure is liver re-transplantation (LR). LR requires extensive surgical expertise and experienced decision making process before, during and after the surgical procedure. The use of DCD liver grafts for LR is controversial. To date there has not been any specific report in the literature regarding the short- and long-term outcomes when DCD grafts were used for LR. This report reviews our program's experience, specifically addressing peri-operative complications and short- and long-term outcomes of patients who received DCD liver grafts for LR.

Material and Methods

Mayo Clinic Florida database was searched for all patients between February 1998 and June 2010 for patients who had undergone LR with DCD liver grafts. All liver grafts were procured by surgeons from our center and University of Wisconsin solution was used for preservation solution. Patient demographics including age, sex, date of initial transplantation, date of LR, number of days between initial and LR, primary liver disease, reason for LR, calculated Model for End-Stage Liver Disease (MELD) score on the day of LR, hospital or ICU stay care after LR, and complications. Operative data included recipient warm ischemia time (WIT) defined as time of removal of liver allograft from cold solution until reperfusion, operative time, and number of units red blood cells transfused. Donor surgery characteristics recorded included donor age, race, sex, cause of death, donor warm ischemia time (DWIT) defined as withdrawal of support to initial flush of preservation solution, and cold ischemia time (CIT) defined as initial flush of preservation solution until the removal from cold in the recipient operation. Donor Risk Index (DRI) was calculated retrospectively for each case. The study protocol was reviewed and approved by Mayo Clinic Institutional Review Board.

In DCD donors, withdrawal of support and declaration of death were in strict compliance with donor hospital policies. The transplant team was not involved in the withdrawal process. An independent physician from the donor hospital, separate from the OPO and the transplant center, was assigned to withdraw artificial life support and provide end of life care to the patient. Following the declaration of death by the independent physician a further 2–5 min of mandatory observation was performed as described in the 1997 Institute of Medicine Guidelines.6 During the 2–5 min waiting period, the patient was transported to the operating room (if not already there) and prepared for organ recovery. Heparin was administered to the patient according to the donor hospital policy. Following the 2–5-min wait period a rapid retrieval technique was performed as described previously. All LR were performed using the piggyback technique without a porto-caval shunt or caval clamping. Standard triple-drug immunosu-ppression with tacrolimus, mycophenolate mofetil and corticosteroids was used in all cases.

Continuous data were reported as mean with range listed. Categorical data were compared with the Chi-square or the Fisher exact test. Long term survival was estimated using Kaplan-Meier analysis by Log Rank testing. Significance was defined at a p value of < 0.05.

Results

Between February 1998 and June 2010, 211 patients underwent liver transplantation using DCD liver grafts; of those 10 patients underwent LR with DCD grafts. Demographic data are given in table 1. Mean recipient age was 50.9 years (range 48-69). Mean MELD scores at the time of LR was 25.6 (range 10–40). Three patients received LR for recurrent Hepatitis C, 4 patients received LR within 60 days of their initial transplant secondary to technical and early graft complications. One patient was retransplanted for chronic rejection, 1 for biliary necrosis and 1 for recurrent PSC.

Table 1..

Demographic data of the recipients.

Patient  Age  Sex  MELD score  Primary disease  Reason for LR  OLT-LR interval 
69  29  Hepatitis C  Hepatitis C  146 
57  31  Hepatitis C  Hepatitis C  489 
49  10  Alcohol  Biliary necrosis  174 
61  17  PSC  HAT  49 
50  16  PSC  PSC  2,932 
48  40  Hepatitis C  PNF  21 
55  35  Hepatitis C  Graft failure  24 
48  25  Hepatitis C  Hepatitis C  301 
47  37  Cryptogenic  Chronic rejection  199 
10  50  16  Hepatitis C  Biliary necrosis  13 

Donor and recipient operative data are given in table 2. Donor age was 36.6 (range 19–54) years. Five donors died from trauma, 2 from stroke, 2 from intracranial hemorrhage, and 1 from myo-cardial infarction. The DWIT was 25.3 min (range 18-63) and CIT was 365.8 min (range 247–486). Recipient WIT was 29.2 min (range 21–38), operative time was 275.1 min (range 131–404), and number of packed red blood cell units was 16.9 (range 3-34) transfused. Mean DRI score was 1.73 (range 1.4–2.2).

Table 2..

Donor and operative data.

Patient  Donor (age)  DRI  Donor WIT (min)  Donor CIT (min)  Recipient WIT (min)  Operative Time (min)  PRBC (units) 
19  1.4  20  320  29  254  25 
57  2.1  18  389  36  271  18 
41  1.6  63  438  38  344 
31  1.7  20  343  32  282  12 
54  2.2  18  458  24  332  38 
48  1.6  17  247  23  131 
20  1.4  13  279  38  317  10 
23  1.9  29  336  21  198  13 
37  1.9  25  486  26  404  34 
10  36  1.8  30  362  25  218 

Post-operative complications and outcomes are listed in table 3. Five (50%) patients had no postoperative complications. One patient died in the operating room from a cardiac arrest. One patient had primary non-function that required a third transplant 12 days later. Three died from complications of sepsis and none of those patients ever left the hospital in the post transplant period. Recipients who had peri-operative death or graft loss (due to PNF) had mean MELD score of 34.4, while the recipients who survived long term had mean MELD score of 16.8 (p = 0.0004). Patients who survived long term did not have any complications necessitating return to the OR, other invasive procedures or readmission. Similarly, the mean hospital stay in recipients with long-term survival was significantly shorter (18.0 vs. 86.2 days, p = 0.05). Mean DRI score were similar between the long-term survivors and deceased recipients (1.80 vs. 1.68, p = 0.9). The calculated 30 day, 1 year, and 3 year graft survival are 70, 60, and 60%, respectively. The 30 day, 1 year, and 3 year patient survival are 80, 60, and 60%, respectively.

Table 3..

Post-operative outcomes.

Patient  Age  MELD  Primary disease  Reason for LR  OLT-LR interval  Complication  ICU stay (days)  Graft survival (days)  Patient survival (days)  Status  Cause of death 
69  29  Hepatitis C  Hepatitis C  146  Biliary sepsis  20  20  20  Dead  Bile leak, liver abscess 
57  31  Hepatitis C  Hepatitis C  489  PNF  20  12  3133  Alive 
49  10  Alcohol  Biliary Necrosis  174  None  2,460  2460  Dead  Renal failure 
61  17  PSC  HAT  49  None  2,889  2,889  Alive 
50  16  PSC  PSC  2,932  None  2,039  2,039  Alive 
48  40  Hepatitis C  PNF  21  Intra-operative death  Dead  Intra-operative cardiac arrest 
55  35  Hepatitis C  Graft Failure  24  Bleeding, sepsis  161  161  161  Dead  Necrotizing pancreatitis 
48  25  Hepatitis C  Hepatitis C  301  None  1,118  1,118  Alive 
47  37  Cryptogenic  Chronic rejection  199  Peritonitis, sepsis  45  45  45  Dead  Intra-abdominal sepsis 
10  50  16  Hepatitis C  Biliary Necrosis  13  None  2,373  2,373  Dead  Recurrent HCC 
Discussion

Patients with first graft failure requiring LR are commonly seen at most liver transplant centers. The most appropriate use of scarce livers continues to evolve. As the gap between supply and demand for liver grafts is widening world wide, livers from DCD donors should be considered. DCD grafts have been used more extensively since 1997 when Institute of Medicine determined that these organs are medically effective and ethically acceptable DCDs are considered to be less than optimal for transplantation because of damaging effect of variable warm ischemia time before cold preservation.4,5

LR causes controversy in the medical, economical and ethical fields as overall graft and patient survival is less than those undergoing initial OLT. The combination of the limited donor organ pool, increased number of patients dying on the waiting list and financial constraints with a failing graft challenges the current organ allocation system to provide efficient distribution of a limited resource.6 The discrepancy between the number of available organs and increasing number of potential recipients will worsen until significant future advances are made in providing alternative management for chronic liver disease. Allocation of scarce liver grafts, especially for LR, requires balancing of ethical principles: beneficence, fairness and utility. LR can be regarded as unfair because some patients get multiple liver grafts, whereas other patients die awaiting their first OLT. LR is commonly denied on the basis of historical poorer outcomes compared to first OLT.7 With increasing life span after OLT, and thus with increase chance of recurrent primary disease in allograft, the transplant community will likely face increased number of OLT recipients with graft failure. LR candidates represent a complicated group and have a more rapid rate of decompensation with a higher rate of postoperative morbidity and mortality than primary OLT candidates.

To date there has not been any specific report regarding the use of DCD liver grafts in the LR setting. The main finding of this retrospective study is that when DCD grafts were used for sick patients with high MELD scores for LR, the patient and graft survivals were prohibitively low. In our experience the only patients who survived long term were the ones with MELD scores ≤ 25 at the time of LR.

This is a single center descriptive analysis of LR recipients managed with uniform surgical technique and medical protocols throughout the study period with complete long-term follow-up. As such, it is a unique contribution to the literature. This study was limited by the relatively small sample size of LR patients who received DCD liver grafts. Small sample size does not permit a multivariable analysis to determine overlapping factors. Another limitation is its retrospective design which spun over a decade. It is possible that other variables, such as significant advances in peri-operative critical care in the last decade could have influenced outcome differences.

Conclusion

Utilization of DCD liver grafts for LR resulted in poor patient outcomes in recipients with moderate to high MELD score. There is further need for reports from other large liver transplant programs and comparative analyses of LR using liver grafts from DCD and brain dead donors.

References
[1.]
Grewal HP, Willingham DL, Nguyen J, Hewitt WR, Taner BC, Cornell D, et al.
Liver transplantation using controlled donation after cardiac death donors: an analysis of a large single-center experience..
Liver Transplant, 15 (2009), pp. 1028-1035
[2.]
Doyle HR, Morelli F, McMichael J, et al.
Hepatic retransplantation: an analysis of risk factors associated with outcome..
Transplantation, 61 (1996), pp. 1499-1505
[3.]
Institute of Medicine DoHCS..
Non-heart-beating organ transplantation:.
Medical and Ethical Issues in Procurement., National Academy Press, (1997),
[4.]
Foley DP, Fernandez LA, Leverson G, Chin LT, Krieger N, et al.
Donation after cardiac death: the University of Wisconsin experience with liver transplantation..
Ann Surgery, 242 (2005), pp. 724-731
[5.]
Pine JK, Aldouri A, Young AL, Davies MH, Attia M, et al.
Liver transplantation following donation after cardiac death: an analysis using matched pairs..
Liver Transplant, 15 (2009), pp. 1072-1082
[6.]
Biggins SW, Beldecos A, Rabkin JM, et al.
Retransplantation for hepatic allograft failure: prognostic modeling and ethical considerations..
Liver Transplant, 8 (2002), pp. 313-322
[7.]
Watt K, Lyden ER, McCashland TM.
Poor survival after liver retransplantation: is hepatitis C to blame?.
Liver Transplant, 9 (2003), pp. 1019-1024
Copyright © 2011. Fundación Clínica Médica Sur, A.C.
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos